Adamas Pharmaceuticals
ADMS
ADMS was delisted on the 23rd of November, 2021.
63 hedge funds and large institutions have $151M invested in Adamas Pharmaceuticals in 2015 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 24 increasing their positions, 11 reducing their positions, and 4 closing their positions.
300% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 4
118% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 11
21% more funds holding
Funds holding: 52 → 63 (+11)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
23% less capital invested
Capital invested by funds: $196M → $151M (-$45.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$10.3M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$7.5M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$4.37M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$3.29M |
| 5 |
Fidelity International
Hamilton,
Bermuda
|
+$2.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CPH
C Partners Holding
Zurich,
Switzerland
|
-$6M |
| 2 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$302K |
| 3 |
GS
Gagnon Securities
New York
|
-$216K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$208K |
| 5 |
Goldman Sachs
New York
|
-$201K |
ADMS Hedge Fund Activity: Q1 2015 in Review
63 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Adamas Pharmaceuticals (ADMS) for Q1 2015, worth a combined $151M — down 23% from $196M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new ADMS positions and 4 closed out — a net gain of 12 holders — while 24 added to existing stakes and 11 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $10.3M. The largest seller was C Partners Holding, cutting an estimated $6M.
- 63 institutional investors held Adamas Pharmaceuticals (ADMS) as of Q1 2015, up from 52 in Q4 2014.
- Funds reported $151M of Adamas Pharmaceuticals stock for Q1 2015, down 23% quarter-over-quarter.
- 16 funds opened new Adamas Pharmaceuticals positions in Q1 2015 and 4 closed out, a net change of +12 holders.
- The largest Adamas Pharmaceuticals buyer in Q1 2015 was Fidelity Investments, an estimated $10.3M added.
- The largest Adamas Pharmaceuticals seller in Q1 2015 was C Partners Holding, an estimated $6M sold.
Based on aggregated 13F filings for Q1 2015.